Healthcare M&A and Valuation
News and Insights

In October 2025, ARCHIMED Diagnostics, the diagnostics-focused arm of global healthcare investment firm ARCHIMED, completed its acquisition of a 60% majority stake in ARK Diagnostics, Inc., a Fremont, California-based developer and manufacturer of specialty in vitro diagnostic (IVD) assays and tests, from South Korean specialty chemical company Soulbrain Holdings. The transaction values ARK at approximately $428 million enterprise value, with Soulbrain retaining a 40% minorit

On October 2, 2025, New Enterprise Associates (NEA)  completed a take private transaction  involving NeueHealth, Inc., a provider of value-based care solutions that integrates patient engagement, care coordination, and provider enablement tools aimed at improving clinical outcomes and reducing total cost of care. NeueHealth’s platform partners with provider organizations and payors to deliver risk-bearing care models, leveraging data analytics, technology-driven workflows, an